Introduction
============

Elevated blood pressure (BP) is a major risk factor for cardiovascular (CV) events, and subsequently, it is also a leading contributor to the global disease burden. Overwhelming evidence suggests that prompt BP control leads to reduction in CV events. To address this issue, the European Hypertension Guidelines issued by the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) recommend initiation of antihypertensive therapy stratified according to stage of hypertension.[@b1-por-10-009] Patients with stage 1 hypertension received monotherapy, while patients with stage 2 a combination therapy, preferably in a single pill. Despite these recommendations, this strategy has not been tested widely in clinical trials.

In the ACCELERATE study, the strategy of initial combination of aliskiren and amlodipine was tested for superiority to each monotherapy in early control of BP without excess of adverse events.[@b2-por-10-009] Patients with SBP between 150 and 180 mmHg were randomized to one of the three groups. Initial combination therapy had a 6.5 mmHg greater reduction in mean SBP than the monotherapy groups without increase in adverse events. However, in this study, patients were not stratified according to stages of hypertension as recommended by the guidelines.

Hypertension guidelines also propose the out-of-office BP measurement in the diagnosis and management of hypertension.[@b1-por-10-009],[@b3-por-10-009],[@b4-por-10-009] Twenty-four-hour ambulatory BP monitoring (ABPM) provides a greater number of readings and mini-mization of the white coat effect, observer bias, and possible measurement errors. This contributes to better diagnostic accuracy and prediction of target-organ damage and adverse CV outcome compared with office BP measurement.[@b5-por-10-009],[@b6-por-10-009] In addition to elevated mean levels of BP, also short-term daytime or 24-hour BP variability (BPV) has been shown to carry an independent prognostic value in hypertensive patients,[@b7-por-10-009],[@b8-por-10-009] and is directly related to target-organ damage.[@b9-por-10-009],[@b10-por-10-009]

Automated office BP (AOBP) is currently gaining recognition as a preferred method of measuring BP, as it correlated closely with 24-hour daytime ambulatory BP, and is a better predictor of target-organ damage than traditional office measurement.[@b4-por-10-009],[@b10-por-10-009]

With the growing acknowledgment of the importance of these factors, this Phase IV study was designed to gather more knowledge on the efficacy of a stratified guideline approach on AOBP, 24-hour ambulatory BP, and BPV in treatment-naïve patients with systolic hypertension using lercanidipine for stage 1 and lercanidipine/enalapril for stage 2.

Patients and methods
====================

Participants
------------

This was an open-label, prospective interventional study conducted in 22 general practices in South Africa. The trial was approved by Pharma Ethics, South Africa, on February 2015 (reference number 141110708), and all patients provided written informed consent prior to treatment start, but the study was not registered as a clinical trial. Adult (\>35 years) treatment-naïve patients or those without anti-hypertensive treatment for \>4 weeks with stage 1 or stage 2 hypertension based primarily on office SBP were assigned to lercanidipine 10 mg (if in stage 1) or to a single pill combination of lercanidipine 10 mg/enalapril 10 mg (if in stage 2). The choice of antihypertensive therapy was based on the ESH/ESC Hypertension Guidelines where a calcium channel blocker (CCB) or a combination of a CCB and an angiotensin-converting-enzyme (ACE) inhibitor can be initiated as first-line therapy.[@b1-por-10-009]

The major exclusion criteria were: body mass index (BMI) \>35 kg/m^2^; pregnancy or planned pregnancy; lactation; previous diagnosis of stage 3 hypertension (BP ≥180/110 mmHg); use of any other agent registered for the use in hypertension; hypersensitivity to any dihydropyridine CCB or any ACE inhibitor; estimated glomerular filtration rate (eGFR) \<60 mL/min (based on the Modification of Diet in Renal Disease study equation); and history of angioedema and strong inhibitors of CYP3A4.

Procedures
----------

AOBP was performed according to the South African Hypertension guidelines using a (Welch Allyn 6100) monitor.[@b11-por-10-009] We used a mean of three readings 1 minute apart after 5 minutes rest in the seated position with the arm supported at heart level. Stage 1 was defined as 140 ≤ SBP ≤ 159 and 90 ≤ DBP ≤ 99; stage 2 as 160 ≤ SBP ≤ 179 and 100 ≤ DBP ≤ 109.

The trial flow diagram is outlined in [Figure 1](#f1-por-10-009){ref-type="fig"} and procedures in [Table 1](#t1-por-10-009){ref-type="table"}. After informed consent, we did an initial screening visit, drew safety bloods for potassium and creatinine, and performed an electrocardiogram (ECG). Eligibility was established at this visit based on the mean of the AOBP, and patients underwent a 24-hour ABPM using a (Welch Allyn 6100) monitor prior to baseline visit. At baseline, patients were assigned to monotherapy or combination therapy according to stage of hypertension. At 6 weeks, office BP, potassium, and creatinine were repeated. Patients not at target (BP \>140/90 mmHg) were up-titrated -- lercanidipine to lercanidipine 10 mg/enalapril 10 mg and lercanidipine 10 mg/enalapril 10 mg to lercanidipine 10 mg/enalapril 20 mg. After 12 weeks (end of study), patients underwent repeat 24-hour ABPM, office BP, ECG, potassium, and creatinine.

The primary end point was changes in AOBP from baseline, at week 6 and week 12, and the percentage of patients reaching target. The secondary end points were: changes in 24-hour ABPM and BPV. The BPV was calculated from the SD of both the daytime and nighttime SBP and DBP during the 24-hour ABPM. Only patients with a successful ABPM at both baseline and week 12 were considered for analysis. Discontinuation and adverse events were recorded.

Statistical analysis
--------------------

All data were captured on the electronic data management system. The sample size was calculated to be a total of 196 patients -- 98 patients in stage 1 and 98 patients in stage 2 hypertension. This assumed that the clinical effect of interest is a decrease in SBP of 10 mmHg with a SD of 25 mmHg with an 80% power to detect a difference with a significance level of 5%. The patient's demographic and clinical outcomes were presented as mean (± SD) or median (with interquartile range) for normally distributed and non-normally distributed data, respectively. Categorical variables were analyzed by chi-squared or Fisher's exact test, while comparison of continuous variables between groups was analyzed using Student's *t*-test or Wilcoxin rank-sum test using Statistica™ version 13.3.

Results
=======

Of the 198 patients included in the study, 48% had stage 1 and 52% had stage 2 hypertension. The mean age was 55 years and BMI was 29.2 kg/m^2^. The demographic breakdown was as follows: 48.5% were female, 51.5% male, 15.1% diabetic, 24.2% white, 38.4% black, 18.7% mixed ancestry, and 18.7% Asian.

The mean (SD) office SBP and DBP and pulse rate are presented in [Figure 2](#f2-por-10-009){ref-type="fig"}. During treatment, 35.7% of stage 1 patients and 32% of stage 2 patients reaching week 6 were up-titrated. At the final visit (week 12), 73.6% of patients achieved control of DBP and 58.6% of SBP ([Table 2](#t2-por-10-009){ref-type="table"}). For group 1 it was 79.5% for diastolic and 59% for systolic, and for group 2 it was 68% for diastolic and 58% for systolic BP.

BP response according to ethnic group is shown in [Table 3](#t3-por-10-009){ref-type="table"}. All ethnic groups showed highly significant improvements in SBP and DBP.

Twenty-hour ABPM was performed in 85 patients, but only 66 had successful ABPM readings at both baseline and 12 weeks. Seventy percent of patients were non-dippers based on SBP. The mean (SD) systolic and diastolic daytime ABPM and the nighttime ABPM at 12 weeks showed a significant reduction vs the baseline measurements ([Table 2](#t2-por-10-009){ref-type="table"}). BPV was also significantly reduced as determined by the SD of 24-hour ABPM readings.

There were 26 discontinuations from the study -- nine due to adverse events, ten were lost to follow-up, three withdrew consent, two due to investigator decision, and two for various reasons.

Adverse events of interest are shown in [Table 4](#t4-por-10-009){ref-type="table"}. The majority of adverse events recovered. There were four serious adverse events unrelated to study drug namely diverticulitis, inguinal hernia, asthma, and severe upper respiratory tract infection.

Safety bloods at screening, week 6, and week 12 showed no significant change in serum K^+^, creatinine, and eGFR at weeks 6 and 12.

Discussion
==========

BP control remains suboptimal in many countries for complex reasons. However, a combination of physician inertia and patient non-adherence are important contributory factors. The ESH Guidelines has recommended the wider use of single pill combinations to improve adherence and initiation of two drugs in combination for patients with more severe hypertension or high CV risk to counter physician inertia.[@b1-por-10-009] However, few studies have tested this approach in clinical practice.

In this study, we tested this approach by using mono-therapy with a CCB (lercanidipine) for stage 1 hypertension and lercanidipine/enalapril single pill combination for stage 2 over a 12-week period with up-titration at 6 weeks. ([Table 1](#t1-por-10-009){ref-type="table"}, [Figure 1](#f1-por-10-009){ref-type="fig"}). This was done in a diverse patient population with 48.5% being female, 15.1% diabetic, 24.2% white, 38.4% black, 18.9% mixed ancestry, and 18.9% Asian with approximately equal numbers of patients with stage 1 and 2 hypertension. During treatment, 35.7% of stage 1 patients and 32% of stage 2 patients were up-titrated. At 12 weeks, 73.6% of patients achieved control of DBP and 58.6% of SBP. There were also highly significant reductions in both SBP and DBP ([Figure 2](#f2-por-10-009){ref-type="fig"}). BP response was observed across all ethnic groups including blacks, mixed ancestry, whites, and Asians. There was a slight but significant rise in mean pulse rate of 3.2 beats per min at week 6, which was well described after instituting a dihydropyridine CCB but was not clinically relevant.[@b12-por-10-009]

Twenty-four-hour ABPM was obtained in 68 patients at both baseline and 12 weeks. It is important to note that non-dipping status for SBP was present in 70.5% of patients undergoing 24-hour ABPM. There were highly significant reductions in overall 24-hour, daytime, and nighttime systolic and diastolic BP as well as reductions in BPV ([Table 2](#t2-por-10-009){ref-type="table"}).

These reductions in BP and BPV are likely to translate into significant reduction in CV and stroke events. However, to improve control rates, it is suggested that single pill combination therapy should be considered in patients at a level of SBP 150 and not 160 mmHg, especially in patients at higher CV risk.

The approach to treatment in this study was associated with very few adverse events related to study drug. In particular, there was only one documented case of hypotension and three cases of dizziness that were possibly related to low BP. There was no significant change in kidney function or serum K^+^. In relation to the individual antihypertensive drugs used in this study, remarkably only 1% of patients were documented to have ankle edema, which is often an important reason for discontinuation of dihydropyridine CCBs. This is probably related to the intrinsic properties of lercanidipine and the reduction of edema due to combination with renin-angiotensin blocker.[@b13-por-10-009],[@b14-por-10-009] In regard to enalapril, there was one case of mild angioedema and a low incidence of dry cough (3.25%). Other published data suggest that the combination of a dihydropyridine CCB reduces the incidence of ACE-inhibitor cough.[@b15-por-10-009]

Limitations of the study were that the participants were not randomized, adherence was not analyzed, and the study was of a relatively short duration. In addition, not all patients underwent 24-hour ABPM and the sample size was small.

Conclusion
==========

A guideline approach using lercanidipine and lercanidipine/enalapril for stage 1 and 2 hypertension, respectively, resulted in highly significant improvements in office SBP and DBP, overall 24-hour BP, daytime BP, and nighttime BP, plus a significant reduction in BPV with few adverse effects. This is also likely to result in better adherence and reduced side effects, and a reduction in CV events.
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###### 

Outline of study protocol and procedures

  ---------------------------------------------------------------------------------------------------------------------------------
                   Screening          Baseline        6 weeks                                                    12 weeks
  ---------------- ------------------ --------------- ---------------------------------------------------------- ------------------
  **Procedures**   AOBP×3\            AOBP×3\         AOBP×3\                                                    AOBP×3\
                   ECG\               ABPM            K^+^, creatinine                                           ABPM\
                   K^+^, creatinine                                                                              ECG\
                                                                                                                 K^+^, creatinine

  **Stage 1 HT**                      lerc10          lerc10\                                                    EOS
                                                      [\*](#tfn1-por-10-009){ref-type="table-fn"}lerc10/enal10   

  **Stage 2 HT**                      lerc10/enal10   lerc10/enal10\                                             EOS
                                                      [\*](#tfn1-por-10-009){ref-type="table-fn"}lerc10/enal20   
  ---------------------------------------------------------------------------------------------------------------------------------

**Note:**

not at target.

**Abbreviations:** ABPM, 24 hour ambulatory BP; AOBP, automated office blood pressure; ECG, electrocardiogram; enal, enalapril; EOS, end-of-study; HT, hypertension; lerc, lercanidipine.

###### 

Changes in 24 hour day and night time BP, and BPV at baseline and 12 weeks

  Parameter                                                             Baseline   12 weeks   p value
  --------------------------------------------------------------------- ---------- ---------- -----------
  Daytime SBP (mmHg)                                                    157        142        p\<0.0001
  Daytime systolic BPV[\*](#tfn3-por-10-009){ref-type="table-fn"}       16.6       14.4       p=0.01
  Daytime DBP (mmHg)                                                    88         81         p\<0.001
  Daytime diastolic BPV[\*](#tfn3-por-10-009){ref-type="table-fn"}      12.3       10.89      p=0.01
  Night time SBP (mmHg)                                                 146        133        p\<0.0001
  Night time systolic BPV[\*](#tfn3-por-10-009){ref-type="table-fn"}    15.7       13.9       p=0.04
  Night time DBP (mmHg)                                                 79.5       72.5       p\<0.009
  Night time diastolic BPV[\*](#tfn3-por-10-009){ref-type="table-fn"}   11.6       10.1       p=0.02

**Note:**

based on SD of 24 hour ABPM.

**Abbreviations:** BPV, BP variability; ABPM, 24-hour ambulatory BP monitor; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.

###### 

BP response in mmHg according to ethnic group

  Ethnic group                 Baseline (SD)   Week 12 (SD)   p value
  ---------------------------- --------------- -------------- ------------
  **Mixed ancestry (18.7%)**                                  
  Systolic BP                  162.5 (12)      138.6 (17.3)   p\<0.00001
  Diastolic BP                 93.9 (9.4)      80.3 (17.7)    p\<0.00002
  **Black (38.4%)**                                           
  Systolic BP                  156.1 (14.7)    142.7 (17.5)   p\<0.00002
  Diastolic BP                 89.9 (12.1)     83.5 (14.3)    p=0.01
  **Asian (18.7%)**                                           
  Systolic BP                  160.2 (13.6)    132.2 (16.8)   p\<0.00001
  Diastolic BP                 91.5 (9.4)      78.3 (6.9)     p\<0.00001
  **White (24.2%)**                                           
  Systolic BP                  155.9 (13.4)    138 (10.7)     p\<0.00001
  Diastolic BP                 94.8 (9.5)      84.2 (10.7)    p\<0.00002

**Abbreviations:** BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.

###### 

Adverse events of interest

  Adverse event                  N (%)                                                 Outcome
  ------------------------------ ----------------------------------------------------- -------------
  Cough                          8 (3.25)[\*](#tfn6-por-10-009){ref-type="table-fn"}   Recovered
  Edema                          2 (1)                                                 Recovered
  Angioedema                     1 (0.7)[\*](#tfn6-por-10-009){ref-type="table-fn"}    Recovered
  Worsening of kidney function   2 (1)                                                 Recovered
  Hypotension                    1 (0.5)                                               Recovered
  Dizziness                      3 (1.5)                                               Recovered
  Uncontrolled BP                7 (3.6)                                               1 recovered

**Note:**

Percentage based on 135 patients exposed to enalapril.

**Abbreviation:** BP, blood pressure.
